



PATENTS

Attorney Docket No. ISA-012.01


IM0060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Leong Ng)	
Application No:)	Art Unit: Not yet known
10/719,695)	
Filed: November 21, 2003)	Confirmation No.: Not yet assigned
For: BODILY FLUID MARKERS OF)	
TISSUE HYPOXIA)	Examiner: Not yet known

CERTIFICATE OF MAILING

I hereby certify that the following paper is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 16, 2004.


John R. Barretto

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION-DISCLOSURE STATEMENT


Applicant hereby brings to the Examiner's attention the references listed on the accompanying form PTO-1449. A copy of each listed reference is enclosed.

To the extent required by 37 C.F.R. §1.98(a)(3), Applicant has described what Applicant considers to be the relevance of any foreign-language reference.

Please charge any additional fee occasioned by this paper to our Deposit Account
No. 06-1448, Reference ISA-012.01.

Respectfully submitted,

Date: June 16, 2004
Customer No: 25181
Patent Group
Foley Hoag, LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Beth E. Arnold, Reg. No. 35,430
Attorney for Applicant
Tel. No. (617) 832-1294
Fax. No. (617) 832-7000



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/719,695
				Filing Date	November 21, 2003
				First Named Inventor	Leong Ng
				Art Unit	
				Examiner Name	Not yet known
Sheet	2	of	3	Attorney Docket Number	ISA-012.01


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	AD	Ames et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14," Nature, 401: 282-286 (1999)	
	AE	Brenner et al., "Diverse Biological Actions of Atrial Natriuretic Peptide," Physiol. Rev., 70(3): 665-699 (1990)	
/	AF	Davies et al, "Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study," Lancet , 358: 439-444 (2001)	
/	AG	Hall, "The value of natriuretic peptides for the management of heart failure: current state of play," Eur J Heart Fail, 3:395-397 (2001)	
/	AH	Hobbs et al, Br Med J 2002; 324: 1498-1502	
/	AI	Ikeda et al, "Cloning and expression of cDNA encoding the human 150 kDa oxygen-regulated protein, ORP150," Biochem Biophys Res Commun, 230(1): 94-9 (1997)	
/	AJ	Karl et al, "Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit," Scand J Clin Lab Invest Suppl, 230:177-181 (1999)	
	AK	Koller et al., "Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)," Science, 252:120-123 (1991)	
/	AL	Kuwabara et al., "Purification and Characterization of a Novel Stress Protein, the 150-kDa Oxygen-regulated Protein (ORP150), from Cultured Rat Astrocytes and Its Expression in Ischemic Mouse Brain," J Biol Chem, 271(9): 5025-5032 (1996)	
/	AM	McDonagh et al, "Biochemical detection of left-ventricular systolic dysfunction," Lancet, 351:9-13 (1998)	
/	AN	McDonagh et al, "Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population," Lancet, 350: 829-833 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/719,695
Filing Date	November 21, 2003
First Named Inventor	Leong Ng
Art Unit	
Examiner Name	Not yet known
Attorney Docket Number	ISA-012.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/	AO	Ng et al, Clinical Science 2002; 102: 411-416	
/	AP	Stingo et al., "Cardiovascular and renal actions of C-type natriuretic peptide," Am. J. Physiol., 262:H308-H312 (1992)	
/	AQ	Stingo et al., "Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma," Am. J. Physiol., 263:H1318-H1321 (1992)	
/	AR	Suga et al., "Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Transforming Growth Factor- β ," J. Clin. Invest., 90:1145-1149 (1992)	
/	AS	Sumar et al., "Lectins as Indicators of Disease-Associated Glycoforms," In: Gabius H-J & Gabius S (eds.), 1993, Lectins and Glycobiology, at pp. 158-174	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.